As of May 24, 2025, IRadimed Corp (IRMD) reports a ROE (Return on Equity) of 22.15%.
ROE (Return on Equity) measures how well a company generates profits from shareholders' investments, indicating equity efficiency.
Historical Trend of IRadimed Corp's ROE (Return on Equity)
Over recent years, IRadimed Corp's ROE (Return on Equity) has shown significant volatility. The table below summarizes the historical values:
| Date | ROE (Return on Equity) |
|---|---|
| 2024-12-31 | 22.15% |
| 2023-12-31 | 24.07% |
| 2022-12-31 | 17.42% |
| 2021-12-31 | 12.93% |
| 2020-12-31 | 2.23% |
This slight upward trend highlights how IRadimed Corp manages its efficiency in generating profits from shareholders' equity over time.
Comparing IRadimed Corp's ROE (Return on Equity) to Peers
To better understand IRadimed Corp's position, it's useful to compare its ROE (Return on Equity) against industry peers. Below are selected comparisons:
| Company | ROE (Return on Equity) |
|---|---|
| IRadimed Corp (IRMD) | 22.15% |
| BioSig Technologies Inc (BSGM) | 996.94% |
| Avinger Inc (AVGR) | 295.39% |
| Nemaura Medical Inc (NMRD) | 119.73% |
| Acutus Medical Inc (AFIB) | 82.36% |
| IDEXX Laboratories Inc (IDXX) | 55.65% |
Compared to its competitors, IRadimed Corp's ROE (Return on Equity) is among the highest compared to peers, suggesting efficient use of shareholder equity to generate profits.